Back to User profile » Dr Maju Mathews

Papers published by Dr Maju Mathews:

Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials

Borentain S, Williamson D, Turkoz I, Popova V, McCall WV, Mathews M, Wiegand F

Neuropsychiatric Disease and Treatment 2021, 17:3459-3470

Published Date: 30 November 2021

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis

Li G, Keenan A, Daskiran M, Mathews M, Nuamah I, Orman C, Joshi K, Singh A, Godet A, Pungor K, Gopal S

Patient Preference and Adherence 2021, 15:2239-2248

Published Date: 2 October 2021

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia

Lambert M, Sanchez P, Bergmans P, Gopal S, Mathews M, Wooller A, Pungor K

Neuropsychiatric Disease and Treatment 2020, 16:3197-3208

Published Date: 23 December 2020

Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire

Blackwood C, Sanga P, Nuamah I, Keenan A, Singh A, Mathews M, Gopal S

Patient Preference and Adherence 2020, 14:1093-1102

Published Date: 2 July 2020

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU

Neuropsychiatric Disease and Treatment 2019, 15:1365-1379

Published Date: 21 May 2019

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

Nash AI, Turkoz I, Savitz AJ, Mathews M, Kim E

Neuropsychiatric Disease and Treatment 2019, 15:731-737

Published Date: 22 March 2019

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study

Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ

Neuropsychiatric Disease and Treatment 2017, 13:2193-2207

Published Date: 17 August 2017